Why the study?
Do NOAC regimens (dabigatran, rivaroxaban, apixaban) prevent VTE and VTE-related death compared to enoxaparin and each other in patients following elective TKR or THR surgery?
Do NOAC regimens (dabigatran, rivaroxaban, apixaban) prevent VTE and VTE-related death compared to enoxaparin and each other in patients following elective TKR or THR surgery?
In a network meta-analysis of NOACs for VTE prevention after joint replacement, dabigatran was inferior to rivaroxaban for VTE prevention, with no significant differences in bleeding or mortality.
Answers are grounded in this paper and cite their sources.
Dabigatran may be less effective than rivaroxaban for post-arthroplasty VTE prevention; challenges NOAC interchangeability in network meta-analyses.
New oral anticoagulant (NOAC) regimens [dabigatran 150 mg (D150) and 220 mg (D220), rivaroxaban 10 mg (R20), and apixaban 2.5 mg bid (A5)] were effective and safe compared to enoxaparin for the prevention of venous thromboembolism (VTE) following elective total knee (TKR) or hip replacement (THR) surgery. First a cluster analysis was used to identify homogeneous studies for the trial programs of each NOAC. Second, only studies reporting VTE and VTE-related death, major bleeding, and mortality were included. The odds ratio (OR) and 95% confidence interval (CI) were calculated for each NOAC regimen versus the comparator. Third, these data were used for the indirect comparison between NOACs. Cluster analysis identified duration of treatment (10 ± 5 and 34 ± 5 days) as the only homogeneous parameter across all NOAC programs (p>0.05) except for A5 and VTE over 10 ± 5 days (analysis not performed). The results of the calculated OR and 95% CI of the four NOAC regimens over 10 ± 5 and 34 ± 5 days showed inferiority of D150 and D220 compared to R10 for VTE (p<0.01, p<0.001). Comparisons of major bleeding and mortality were not different for all indirect comparisons. Despite the lack of standard definitions for VTE and bleeding outcomes, cluster analysis seems to be an appropriate tool to identify homogeneity across trial programs and to perform an indirect comparison for NOACs for prevention of VTE following TKR and THR surgery.
No takes yet. Share an insight, caveat, or question.
Marx et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: